Co‐morbidities and bleeding in elderly patients with haemophilia—A survey of the German, Austrian and Swiss Society of Thrombosis and Haemostasis Research (GTH)

Abstract

The most common co-morbidity of the patient population was hypertension, a considerable part had ischemic heart disease and antiplatelet or anticoagulant drugs.

Mortality in congenital hemophilia A – a systematic literature review

“…23,29 The proportion of deaths from HIV varied widely, from 1% in 2000 through 2010 in a study of people with non-severe HA in Europe/Australia, to 55.9% in 1980 through 1989 in an Italian study of PwH. 23,26 Seven studies reported a peak of HIV-related deaths during the AIDS epidemic in the late 1980s and early 1990s ( Figure 2B), 23,25,28,29,33,36 which decreased from then on. [23][24][25][26]31,33,35 The proportion of deaths due to HCV/HBV infection or hepatic disease ranged from 6% (severe hemophilia) to 32% (severe hemophilia without FVIII inhibitors).…”

“…Nine observational studies published between 2010 and 2020 reported on crude mortality rates and/or mortality ratios; the data in TA B L E 3 Overview of studies reporting cause of death [22][23][24][25][26]28,29,[31][32][33][34][35][36][37][38] these studies spanned 1968 through 2018. [23][24][25][26][27][28][29][30][31] The mortality ratio Table 1).…”

“…A, Primary cause of death in publications ordered by study period, from earliest to most recent. [22][23][24][25][26]28,29,[31][32][33][34][35][36][37][38] Number of deaths in each study is displayed across the top of the chart. B, Primary cause of death among studies that were conducted pre 2010 23,29,33 versus post 2010.…”

“…to 2018. [22][23][24][25][26]28,29,[31][32][33][34][35][36][37][38] Causes were inconsistently categorized, and the most common causes varied according to the population, country, and time period. The most frequently observed causes of death were HIV/HCV/HBV and hepatic disease (32.4%), hemorrhage (21.4%), other (19.4%), and malignancy (9.9%; Figure 2A).…”

“…Study populations were also extremely heterogeneous, encompassing those with congenital and acquired HA/HB of different severities and with various comorbidities, including a pediatric study 38 and a study in PwH older than 60 years of age. 36 Therefore, it is difficult to draw conclusions specifically about PwcHA.…”